Home » Stocks » Iterum Therapeutics

Iterum Therapeutics PLC (ITRM)

Stock Price: $1.19 USD 0.00 (0.00%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 21.23M
Revenue (ttm) n/a
Net Income (ttm) -98.65M
Shares Out 17.84M
EPS (ttm) -6.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $1.19
Previous Close $1.19
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.18
Day's Range 1.12 - 1.20
Day's Volume 2,074,884
52-Week Range 1.12 - 7.65

More Stats

Market Cap 21.23M
Enterprise Value 33.67M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.84M
Float 9.72M
EPS (basic) -6.74
EPS (diluted) -6.73
FCF / Share -6.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 366,880
Short Ratio 0.18
Short % of Float 4.10%
Beta 1.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -94.45M
Net Income -98.65M
Free Cash Flow -91.24M
Net Cash -12.44M
Net Cash / Share -0.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -89.82%
ROE -1,995.15%
ROIC -3,758.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

$4.75*
(299.16% upside)
Low
1.00
Current: 1.19
High
9.00
Target: 4.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue0.040.870.51-
Revenue Growth-95.74%71.06%--
Gross Profit0.040.870.51-
Operating Income-102-76.56-29.46-13.36
Net Income-103-77.06-29.41-13.46
Shares Outstanding14.528.730.170.02
Earnings Per Share-7.10-8.82-170.84-568.87
Operating Cash Flow-78.89-75.89-30.60-11.30
Capital Expenditures-0.02-0.09-0.81-
Free Cash Flow-78.91-75.98-31.42-11.30
Cash & Equivalents4.8384.5839.2224.81
Total Debt13.4314.10--
Net Cash / Debt-8.5970.4839.2224.81
Assets25.7597.8746.7626.92
Liabilities51.9926.257.214.22
Book Value-26.2471.6239.4922.67
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Iterum Therapeutics PLC
Country Ireland
Employees 44
CEO Corey N. Fishman

Stock Information

Ticker Symbol ITRM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ITRM
IPO Date May 25, 2018

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.